International Myeloma Foundation
MYELOMA MINUTE | Up To The Minute News | 5.19.2022
female office laptop working
490x245 Grant.png
IMF Names Recipients of 2022 Brian D. Novis Research Grants
Established in memory of the IMF’s co-founder, the Brian D. Novis Research Grants are traditionally awarded during the “Living Well with Myeloma” patient presentation which takes place every year at the annual meeting and exposition of the American Society of Hematology (ASH). This year, the presentations were conducted online. Since 1994, the IMF has funded more than 150 of the most promising myeloma research projects by talented investigators from leading institutions around the world. The IMF’s commitment to supporting important myeloma research has improved patient outcomes and has brought us closer to fulfilling our mission — the search for a cure. To learn more about the 2022 Brian D. Novis Grant recipients, visit the IMF website or read the full publication of the 2022 Spring Edition of Myeloma Today.
2020LearnMoreButton.png
multiple researchers in lab
Sarclisa (isatuximab) Combination Provides Unprecedented Median Progression Free Survival in Relapsed Multiple Myeloma Patients
The latest results of the Phase 3 IKEMA trial demonstrate the longest median progression free survival (mPFS) on a proteasome inhibitor backbone in patients who relapsed after a prior therapy, including lenalidomide. The median progression free survival increased from 19.2 months to 35.7 months when Sarclisa® (isatuximab) was added to carfilzomib and dexamethasone. Further analysis, following U.S. Food and Drug Administration recommendations on censoring rules, showed mPFS increased from 20.8 to 41.7 months when Sarclisa was added to carfilzomib and dexamethasone. These results, presented at the Controversies in Multiple Myeloma World Congress, represent the longest mPFS among studies investigating a proteasome inhibitor backbone in the second-line setting for the treatment of relapsed multiple myeloma (MM). These data will also be presented at the European Society for Medical Oncology on May 19. To learn more, read Sanofi’s press release.
2020LearnMoreButton.png
hand touching digital images
Join the Fight Against Myeloma by Supporting the IMF’s Novel Research
Patients have always been the primary focus of the IMF’s mission: to improve the quality of life of myeloma patients while working toward prevention and a cure. Patients are at the center of all IMF initiatives, ranging from education to research that will enhance their quality of care and outcomes. IMF programs have made and continue to make significant advances and improvements in the lives of myeloma patients across the IMF’s four founding principles: Research, Education, Support, and Advocacy. Help the IMF collect and study important data to ensure that the right patient gets the right treatment at the right time! To learn more about the IMF’s novel research and how to become a philanthropic partner, visit the IMF website or read the full publication of the 2022 Spring Edition of Myeloma Today.
2020LearnMoreButton.png
rcw men and women in meeting circle
IMF Virtual Regional Community Workshop — Midwest on May 21
The IMF Regional Community Workshop Midwest will be held on Saturday, May 21 at 8:00 a.m. PT/ 9:00 a.m. MDT/ 10:00 a.m. CT/ 11:00 a.m. ET. IMF Senior Director of Regional Community Workshops Kelly Cox will kick off the workshop. Guest speakers include Morie Gertz, MD (Mayo Clinic—Rochester, MN), Al-Ola Abdallah, MD (University of Kansas Medical Center—Kansas City, KS), and IMF Nurse Leadership Board (NLB) Member Teresa Miceli, RN, BSN, OCN (Mayo Clinic—Rochester, MN). The workshop will include an introduction to myeloma, upfront treatments at diagnosis, maintenance therapy, relapse information, and an update on clinical trials. IMF NLB Member Teresa Miceli will talk about managing side effects and symptoms of myeloma and its treatments. After each presentation with the experts, attendees will have ample time to ask questions.
register button
imf comedy fundraiser
Rhode Island Multiple Myeloma Support Group’s Comedy Fundraiser on May 27th at Knights of Columbus Hall   
The Rhode Island Multiple Myeloma Support Group will be holding a Comedy Fundraiser to benefit the IMF, featuring top local comedians on Friday, May 27 at the Knights of Columbus Hall in Warwick, RI. Doors open at 6:00 p.m., the show starts at 7:00 p.m. Tickets are $20 each. For tickets, donations, or sponsorships, please visit www.funny4funds.com/events. Donations are also currently being accepted through the IMF website.  
donate now button
what is car t cell therapy image
#ASKDRDURIE | Dr. Durie's Weekly Web Video Series
What is CAR T-cell therapy?
Watch Now
 
Online Patient Forum

Smart Patients: Join the Conversation
Clinical Trial Fact Sheets

CANOVA Trial (Accruing)

Phase II Relapsed or Refractory Venetoclax Trial (Accruing)

Phase I/II Trial Using a Venetoclax Combination With or Without Bortezomib (Accruing)

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)
Upcoming Events

Learn More
Grand Tour of Scotland Whisky Tasting 

Register Now
14th Annual Czerkies Memorial Golf Outing

Save the Date
Laughs 4 Life Returns
Webinar Replays
Watch the Replay
Regional Community Workshop — Mountain States

Watch the Replay
Regional Community Workshop — West South Central

Watch the Replay
Regional Community Workshop — Tri-State

See also, all of our events.
 

We Thank Our Sponsors:

Bristol Myers Squibb, GSK, Janssen Oncology, and Karyopharm Therapeutics
We also thank individuals like you for your continued support!
Subscribe Button@2x.jpg
2020ButtonDonateBurg.png
Join the conversation at The International Myeloma Foundation
Facebook Facebook: /Myeloma  |  Twitter Twitter @IMFMyeloma  |  Instagram Instagram @IMFmyeloma

www.myeloma.org
This email was sent by:
The International Myeloma Foundation
4400 Coldwater Canyon Ave., Suite 300
Studio City, CA 91604
Connect with the IMF InfoLine
1-800-452-2873
We respect your privacy and your preferences for communications of this nature.
Home  •  Unsubscribe  •  Privacy Policy
View as web page